JAK2 in myeloproliferative disorders is not just another kinase

Cell Cycle

Volumn 4, Issue 8, 2005, Pages 4053-4056

  Tefferi, Ayalew ^a,c   Gilliland, D Gary ^b  

^a Mayo Clinic   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Essential thrombocythemia; JAK2; Janus kinase; Mutation; Myelofibrsis; Myeloproliferative disorders; Polycythemia vera; Tyrosine kinase

Indexed keywords

JANUS KINASE 2;

BONE MARROW; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DOWNSTREAM PROCESSING; ERYTHROCYTE; GENE MUTATION; GENETIC CODE; HUMAN; LEUKOCYTE; MOLECULAR CLONING; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; PHOSPHORYLATION; POLYCYTHEMIA VERA; REVIEW; THROMBOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

MURINAE;

EID: 25444513652     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.8.1872     Document Type: Review

References (57)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW, (eds): WHO classification of tumors: Tumors of the hematopoietic and lymphoid tissues. Lyon, IARC press 2001.
2. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100(7):2292-2302.
3. Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 1951, 6:372-375.
4. Tefferi A, Gilliland DG: Classification of Myeloproliferative Disorders: From Dameshek Towards a Semi-Molecular System. Best Hematology Practice & Research in Clinical Haematology 2005, in press.
5. Tefferi A: Chronic myeloid disorders: Classification and treatment overview. Semin Hematol 2001, 38(1, Suppl 2):1-4.
6. Fialkow PJ: Stem cell origin of human myeloid blood cell neoplasms. Verh Dtsch Ges Pathol 1990, 74:43-47.
7. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. J Natl Cancer Inst 1960, 25:85.
8. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G: Structural organization of the bcr gene and its role in the Ph′ translocation. Nature 1985, 315(6022):758-761.
9. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D: The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986, 233(4760):212-214.
10. McLaughlin J, Chianese E, Witte ON: In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A 1987, 84(18):6558-6562.
11. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247(4944):824-830.
12. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464):1054-1061.
13. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005, in press.
14. Kralovics R, Passamonti F, Buser AS, Soon-Siong T, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
15. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4):387-397.
16. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ: Identification of an acquired JAK2 mutation in Polycythemia vera. J Biol Chem 2005.
17. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A: The JAK2 V617F Activating Tyrosine Kinase Mutation is an Infrequent Event in Both "Atypical" Myeloproliferative Disorders and the Myelodysplastic Syndrome. Blood 2005, Blood First Edition Paper, prepublished online April 28, 2005; DOI 10.1182/blood-2005-03-1183.
18. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlman R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NCP: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, Blood First Edition Paper, prepublished online May 26, 2005; DOI 10.1182/blood-2005-03-1320.
19. Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF: JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 1992, 7(7):1347-1353.
20. Rane SG, Reddy EP: Janus kinases: components of multiple signaling pathways. Oncogene 2000, 19(49):5662-5679.
21. Yamaoka K, Saharinen P, Pesu M, Holt VE, 3rd, Silvennoinen O, O'Shea JJ: The Janus kinases (Jaks). Genome Biol 2004, 5(12):253.
22. Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zurcher G, Ziemiecki A: Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991, 11(4):2057-2065.
23. Yeh TC, Pellegrini S: The Janus kinase family of protein tyrosine kinases and their role in signaling. Cell Mol Life Sci 1999, 55(12):1523-1534.
24. Rane SG, Reddy EP: JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2002, 21(21):3334-3358.
25. Saharinen P, Vihinen M, Silvennoinen O: Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003, 14(4):1448-1459.
26. Kerr IM, Costa-Pereira AP, Lillemeier BF, Strobl B: Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett 2003, 546(1):1-5.
27. Benekli M, Baer MR, Baumann H, Wetzler M: Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 101(8):2940-2954.
28. Levy DE, Darnell JE, Jr.: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3(9):651-662.
29. Starr R, Hilton DJ: Negative regulation of the JAK/STAT pathway. BioEssays 1999, 21(1):47-52.
30. Shuai K, Liu B: Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003, 3(11):900-911.
31. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A: CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 2000, 275(38):29338-29347.
32. Stofega MR, Herrington J, Billestrup N, Carter-Su C: Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol Endocrinol 2000, 14(9):1338-1350.
33. Rawlings JS, Rosler KM, Harrison DA: The JAK/STAT signaling pathway. J Cell Sci 2004, 117(Pt 8):1281-1283.
34. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P: Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90(7):2535-2540.
35. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278(5341):1309-1312.
36. Nguyen MH, Ho JM, Beattie BK, Barber DL: TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3′-kinase/protein kinase B signaling pathway. J Biol Chem 2001, 276(35):32704-32713.
37. Ho JM, Nguyen MH, Dierov JK, Badger KM, Beattie BK, Tartaro P, Haq R, Zanke BW, Carroll MP, Barber DL: TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood 2002, 100(4):1438-1448.
38. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, Lee CK, Gerthner R, Kitamura T, Frantsve J, Anastasiadou E, Loh ML, Levy DE, Ihle JN, Gilliland DG: Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 2000, 6(3):693-704.
39. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005, 65(7):2662-2667.
40. Melzner I, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Barth TF, Leithauser F, Moller P: Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005, 105(6):2535-2542.
41. Ugo V, Marzac C, Teyssandier I, Larbret F, Lecluse Y, Debili N, Vainchenker W, Casadevall N: Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004, 32(2):179-187.
42. Arcasoy MO, Harris KW, Forget BG: A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation. Exp Hematol 1999, 27(1):63-74.
43. Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, Wagner KU: Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis 2004, 40(1):52-57.
44. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF: Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995, 80(5):729-738.
45. Shultz LD, Rajan TV, Greiner DL: Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol 1997, 15(8):302-307.
46. Roder S, Steimle C, Meinhardt G, Pahl HL: STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol 2001, 29(6):694-702.
47. Dai C, Krantz SB: Increased expression of the INK4a/ARF locus in polycythemia vera. Blood 2001, 97(11):3424-3432.
48. Brockman JL, Schroeder MD, Schuler LA: PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol 2002, 16(4):774-784.
49. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL: Expression of Bcl-x in erythroid precursors from patients with polycythemia vera [see comments]. N Engl J Med 1998, 338(9):564-571.
50. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF: Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999, 98(2):181-191.
51. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10(1):105-115.
52. Lindauer K, Loerting T, Liedl KR, Kroemer RT: Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 2001, 14(1):27-37.
53. Saharinen P, Takaluoma K, Silvennoinen O: Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000, 20(10):3387-3395.
54. Saharinen P, Silvennoinen O: The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002, 277(49):47954-47963.
55. Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers MG, Jr.: Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol 2004, 24(11):4968-4978.
56. Tefferi A: Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 2003, 78(2):174-194.
57. Sandberg EM, Ma X, He K, Frank SJ, Ostrov DA, Sayeski PP: Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation. J Med Chem 2005, 48(7):2526-2533.